That shift raises both opportunity and risk. Continuous data can detect treatment effects that single-visit snapshots miss. But the technology introduces new questions about data accuracy, device reliability, and how regulators should interpret streams of measurements gathered outside controlled environments.

How the FDA approaches DHT-based data

In earlier guidance documents and workshop discussions, the FDA has outlined several recurring themes that typically appear in its DHT-related work:

• Verification and validation: sponsors must show that a device measures what it claims to measure, and that the data are reliable across users and conditions
• Clinical meaningfulness: a captured endpoint must reflect something relevant to how a patient feels, functions, or survives
• Privacy and cybersecurity: data flowing from personal devices must meet the same standards expected of any clinical data source
• Generalizability: a tool's performance in a controlled validation study should predict performance in a broader, more diverse trial population

The new resource consolidates access to these topics in one location on fda.gov, the agency noted in its description.

Who should pay attention

Three audiences have a direct stake in the resource:

• Sponsors designing trials, including biomarker-informed companies, who need to know which DHT-generated endpoints the FDA will accept in a marketing application
• Device manufacturers building the sensors and software, who must understand validation expectations
• Investigators and academic researchers, who increasingly propose DHT-based outcome measures in grant applications and protocols

Open questions for the field

Several issues remain unresolved across the industry. Standardization is incomplete: different manufacturers describe similar measurements (for example, "steps per day" or "sleep efficiency") in incompatible ways. Statistical methods for analyzing high-frequency DHT streams are still evolving. And regulatory acceptance of DHT-derived endpoints as primary or secondary trial endpoints varies by therapeutic area.

Limitations of the current resource

The page serves as a navigational hub rather than a binding regulation. Its content directs readers to existing guidance documents, discussion papers, and pilot programs rather than issuing new rules. Sponsors planning DHT-heavy submissions should still consult the underlying guidances for binding commitments.

Researchers and developers can access the full resource directly on the FDA's website at fda.gov.